About 10% of the U.S. population fits into the highest-risk category, with a 20% or higher risk of a cardiac event; 54% are ...

The American College of Cardiology found uneven gains and sobering declines in heart health. "You can't treat your way out of ...

Through its commitment to a data-driven approach to improving cardiovascular health, the Journal of the American College of ...

BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

UM cardiovascular experts lead pioneering stem cell research, developed a nationally recognized AHA certified model for ...

Research reveals the widespread impact of magnesium deficiency on cardiovascular disease, emphasizing the importance of improved dietary intake for public health. Study: The Role of Dietary Magnesium ...

Drs Harrington and Gibson’s annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights.

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

In this study, researchers aimed to characterize cardiometabolic risk factors and cardiovascular disease incidence in racially and ethnically underrepresented women with breast cancer.

NJ Top Docs has reviewed and approved eleven healthcare providers of Hunterdon Cardiovascular Associates for 2025. Our ...

Nordic women with PCOS face a higher risk for cardiovascular disease than those without, with the risk persisting in those ...